Steven King | President and Chief Executive Officer
Mosaic Immunoengineering
Mr. King has more than 15 years as CEO and BOD member of NASDAQ biotechnology company Peregrine Pharmaceuticals. He helped raise over $250M to advance the company's lead product and grow their CDMO business. Steve led the Peregrine team to advance the lead product from discovery through phase 3 clinical trials while growing CDMO revenues from startup to over $55M
Appearances:
Day 3 - November 30 @ 13:45
Development of CPMV-based vaccines against cancer
last published: 02/Jan/24 12:15 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events